Effects of Cilostazol Combined with Donepezil on MMSE Score and Blood-brain Barrier Function in Patients with Cerebral Small Vascular Disease Cognitive Dysfunction
Objective To investigate the effects of cilostazol combined with donepezil on the score of the simple mental status checklist(MMSE)and the function of the blood-brain barrier(BBB)in patients with cerebral small vascular cognitive impairment(CSVCI).Methods 104 patients with CSVCI admitted to Nanyang Central Hospital from January 2021 to March 2023 were selected as the study objects,and were divided into control group and combination group by random number table method,with 52 cases in each group.The control group was treated with donepezil,and the combination group was treated with cilostazol combined with donepezil.The clinical efficacy,MMSE,Montreal Cognitive Assessment Scale(MoCA)score before and after treatment,BBB index,serum associated cytokines[brain-derived nerve growth factor(BDNF),nerve growth factor(NGF),3-nitrotyrosine(3-NT),fibroblast growth factor 23(FGF23)]levels and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the combination group was 94.23%higher than that of the control group 78.85%(P<0.05).After 12 weeks of treatment,MoCA and MMSE scores in combination group were higher than those in control group(P<0.05);the BBB index of the combination group was lower than that of the control group(P<0.05);the serum levels of BDNF and NGF in combination group were higher than those in control group,and the levels of 3-NT and FGF23 were lower than those in control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of cilostazol and donepezil can significantly improve BBB function and neurological function,promote cognitive function and mental state,improve efficacy and safety in CSVCI patients.
CilostazolDonepezilCerebral small vascular diseaseCognitive dysfunction
NETL
NSTL
万方数据
